Company news

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) news

Atara Biotherapeutics, Inc. news releases on 6ix. Latest, Sep 30, 2026: Atara Biotherapeutics Reports that the Tabelecleucel Biologics License Application Has…

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) news

Press releases & updates

Atara Biotherapeutics Reports that the Tabelecleucel Biologics License Application Has Been Resubmitted to the U.S. Food and Drug Administration

Atara Biotherapeutics Reports that the Tabelecleucel Biologics License Application Has Been Resubmitted to the U.S. Food and Drug Administration

Atara Biotherapeutics Announces Second Quarter 2026 Financial Results and Operational Progress

Atara Biotherapeutics Announces First Quarter 2026 Financial Results and Operational Progress

Rajani Dinavahi, MD, Appointed Chief Medical Officer of Ardelyx

Atara Biotherapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Operational Progress

Atara Biotherapeutics Provides Regulatory Update on Tabelecleucel

Atara Biotherapeutics Provides a Business Update

Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLO™ (tabelecleucel)

Atara Biotherapeutics Announces Third Quarter Financial Results and Operational Progress

Pierre Fabre Pharmaceuticals Announces Transfer from Atara Biotherapeutics of the Biologics License Application (BLA) for Tabelecleucel as Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD)

Atara Biotherapeutics Announces Changes to Its Board of Directors

Atara Biotherapeutics Announces Second Quarter Financial Results and Operational Progress

Atara Biotherapeutics Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-cel®) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease

Perre Fabre Pharmaceuticals, Inc. Announces Transfer of Investigational New Drug Application for Tabelecleucel from Atara Biotherapeutics, Inc.

Atara Biotherapeutics Provides Regulatory and Business Updates on Tabelecleucel (Tab-cel®)

Atara Biotherapeutics Appoints James Huang and Nachi Subramanian to Board of Directors

Atara Biotherapeutics Announces First Quarter Financial Results and Operational Progress

Atara Biotherapeutics Announces Pricing of $16 Million Offering

Atara Biotherapeutics Provides Regulatory Updates on EBVALLO™ (tabelecleucel)

Atara Biotherapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Operational Progress

Atara Biotherapeutics Provides Update on Clinical Programs Related to EBVALLO™ (tabelecleucel) and ATA3219

Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLOTM (tabelecleucel)

Atara Biotherapeutics Announces Third Quarter 2024 Financial Results and Operational Progress

Atara Biotherapeutics to Announce Third Quarter 2024 Financial Results on Tuesday, November 12, 2024

Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Atara Biotherapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Atara Biotherapeutics Announces $36 Million Registered Direct Offering

Atara Biotherapeutics Announces Second Quarter 2024 Financial Results, Operational Progress and Leadership Update

Atara Biotherapeutics to Participate in the Canaccord Genuity 44th Annual Growth Conference

Atara Biotherapeutics To Participate at the Stifel Virtual Cell Therapy Forum

Atara Biotherapeutics’ Ebvallo™ (tabelecleucel) Wins Prix Galien International Award for Best Product for Orphan/Rare Diseases

Atara Biotherapeutics Announces 1-for-25 Reverse Stock Split

Atara Biotherapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Atara Biotherapeutics Presents Preclinical Data on ATA3219, an Allogeneic CD19-Targeted CAR T Therapy for the Treatment of B-Cell Driven Autoimmune Diseases, at the ISCT 2024 Annual Meeting

Atara Biotherapeutics Submits Tabelecleucel (Tab-cel®) Biologics License Application for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease with U.S. FDA

Atara Biotherapeutics Announces First Quarter 2024 Financial Results and Operational Progress

Atara Biotherapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Operational Progress

Atara Biotherapeutics Receives FDA Clearance of IND Application in Lupus Nephritis for ATA3219, an Allogeneic CAR T Therapy

Atara Biotherapeutics to Participate in Cell Therapy Panel Discussion at the Cowen 44th Annual Health Care Conference

Atara Biotherapeutics Announces Submission of Investigational New Drug Application for ATA3219 for Treatment of Lupus Nephritis

Atara Biotherapeutics and Pierre Fabre Laboratories Announce Publication of Phase 3 ALLELE Tab-cel® Data in The Lancet Oncology

Atara Biotherapeutics to Present Recent Progress and Key Upcoming Milestones at the 42nd Annual J.P. Morgan Healthcare Conference

Atara Biotherapeutics Announces $15 Million Registered Direct Offering

Atara Biotherapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Atara Biotherapeutics Announces Closing of Expanded Global Tab-cel® Partnership with Pierre Fabre Laboratories

Atara Biotherapeutics Presents Positive Preclinical Data on ATA3431, A Next-Generation Allogeneic CD20/CD19-Targeted CAR, at the 65th ASH Annual Meeting

Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Atara Biotherapeutics To Present Positive New Tab-cel® Clinical Data During Oral Session at ESMO Immuno-Oncology Annual Congress 2023

Atara Biotherapeutics to Participate at the 6th Annual Evercore ISI HealthCONx Conference